S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

Bibliographic Details
Main Authors:	A. S. Kubasch, A. Giagounidis, G. Metzgeroth, A. Jonasova, R. Herbst, J. M. T. Diaz, B. De Renzis, K. S. Götze, M.-L. Huetter-Kroenke, M.-P. Gourin, B. Slama, S. Dimicoli-Salazar, P. Cony-Makhoul, K. Laribi, S. Park, K. Jersemann, D. Schipp, K. H. Metzeler, O. Tiebel, K. Sockel, S. Gloaguen, A. Mies, F. Chermat, C. Thiede, R. Sapena, R. F. Schlenk, P. Fenaux, U. Platzbecker, L. Ades
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843568.62728.76

Similar Items

Clinical experience with romiplostim
by: G. B. Kuchma, et al.
Published: (2014-07-01)

Clinical experience with romiplostim
by: G. B. Kuchma, et al.
Published: (2014-07-01)

SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR
by: A. N. Afanasyeva, et al.
Published: (2022-10-01)

Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature
by: Gerald A. Soff, et al.
Published: (2024-08-01)

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
by: D. J. Kuter, et al.
Published: (2015-01-01)

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
by: D. J. Kuter, et al.
Published: (2015-01-01)

Developmental differences between newborn and adult mice in response to romiplostim
by: Katherine A. Sparger, et al.
Published: (2018-05-01)

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
by: Igor Makarenko, et al.
Published: (2023-10-01)

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
by: Cy R. Wilkins, et al.
Published: (2022-03-01)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2017-11-01)

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
by: Francesca Palandri, et al.
Published: (2012-06-01)

Romiplostim as a treatment for immune thrombocytopenia: a review
by: Chalmers S, et al.
Published: (2015-01-01)

P747: LR-MDS IS CHARACTERIZED BY DIFFERENTIAL EXPRESSION OF INFLAMMASOME-RELATED GENES IN SPECIFIC CELL POPULATIONS
by: C. Rolfs, et al.
Published: (2022-06-01)

Experimental Validation a Method for Assessing Neutralizing Antibodies of Romiplostim in Human Plasma
by: A. N. Afanaseva, et al.
Published: (2024-03-01)

Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia
by: Maria Fernanda Gonzalez, et al.
Published: (2012-01-01)

Remissions after long-term use of romiplostim for immune thrombocytopenia
by: Ariela L. Marshall, et al.
Published: (2016-12-01)

Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies
by: Abraham Z. Cheloff, et al.
Published: (2022-11-01)

Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage
by: Romain Gellens, et al.
Published: (2018-01-01)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
by: Tremblay G, et al.
Published: (2018-11-01)

Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes
by: Min‐Ok Ryu, et al.
Published: (2024-07-01)

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
by: Douglas B. Cines, et al.
Published: (2017-08-01)

The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors
by: Hanny Al-Samkari, et al.
Published: (2018-04-01)

Aplastic anemia with thrombopoietin gene mutation successfully treated with romiplostim monotherapy
by: Niranjan Gurunath Hegde, et al.
Published: (2023-01-01)

Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers
by: Sara Moufarrij, et al.
Published: (2024-06-01)

Recovery of Bone Marrow Function in VEXAS Syndrome-potential Role for Romiplostim
by: Adam Al-Hakim, et al.
Published: (2023-08-01)

P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL
by: H. Yamazaki, et al.
Published: (2022-06-01)

Uso de romiplostim en trombocitopenia inmunitaria: experiencia en Cuenca (Ecuador)
by: Héctor Chiang-Wong, et al.
Published: (2024-05-01)

Romiplostim – an emergency treatment of intracranial haemorrhage in the course of severe primary immune thrombocytopaenia
by: Paweł Łaguna, et al.
Published: (2022-12-01)

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review
by: Fernanda Lubiana de Oliveira, et al.
Published: (2023-01-01)

In-silico selection of appropriate signal peptides for romiplostim secretory production in Escherichia coli
by: Masoud Hashemzaei, et al.
Published: (2023-01-01)

Total remission of severe immune thrombocytopenia after short term treatment with romiplostim
by: Efthymia Vlachaki, et al.
Published: (2011-10-01)

Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia – Case Report
by: Zoubi I, et al.
Published: (2025-01-01)

P1632: PROSPECTIVE OBSERVATIONAL STUDY IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) TREATED WITH TPO-R AGONISTS (TPO-RA): ELTROMBOPAG (EPAG) AND ROMIPLOSTIM (ROMI) - THE PEPITE STUDY
by: S. Chèze, et al.
Published: (2022-06-01)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies
by: Hanny Al-Samkari, et al.
Published: (2020-06-01)

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal
by: G Mowatt, et al.
Published: (2009-09-01)

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia
by: Michael D. Tarantino, et al.
Published: (2019-11-01)

Missing Cells - A Rare Case of Persisting Thrombocytopenia in Pregnancy With Dengue and Role of Romiplostim in These Cases
by: Ruchita Sinha, et al.
Published: (2023-06-01)

FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
by: Pierre Peterlin, et al.
Published: (2024-11-01)